Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG1837 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2015
At a glance
- Drugs GLPG 1837 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors Galapagos NV
- 09 Oct 2015 According to Galapagos NV media release, results were presented at the North American Cystic Fibrosis Conference (NACFC) 2015.
- 09 Oct 2015 Results published in a Galapagos NV media release.
- 08 Oct 2015 Results will be presented at the North American Cystic Fibrosis Conference (NACFC) 2015, according to Galapagos NV media release.